low dose tirzepatide vs. Semaglutide for Weight Loss low dose of tirzepatide Zepbound®

Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%

A weakened antioxidant barrier contributes to oxidative changes in cellular biomolecules

Slowing transit during a bacterial infection can extend the illness

Bupropion/naltrexone may cause other less common, but more serious, side effects

That fatty acid attachment is what gives tirzepatide its long half-life in the body